Nordea Investment Management AB Acquires 3,664 Shares of United Therapeutics Corporation $UTHR

Nordea Investment Management AB increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 50.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,914 shares of the biotechnology company's stock after acquiring an additional 3,664 shares during the period. Nordea Investment Management AB's holdings in United Therapeutics were worth $3,146,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. grew its position in United Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock worth $1,374,001,000 after acquiring an additional 15,312 shares during the last quarter. Dimensional Fund Advisors LP grew its position in United Therapeutics by 0.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock worth $192,571,000 after acquiring an additional 4,145 shares during the last quarter. Assetmark Inc. grew its position in United Therapeutics by 20.8% during the 1st quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock worth $159,823,000 after acquiring an additional 89,290 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its position in United Therapeutics by 22.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company's stock worth $147,278,000 after acquiring an additional 87,664 shares during the last quarter. Finally, Invesco Ltd. grew its position in United Therapeutics by 46.1% during the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company's stock worth $143,381,000 after acquiring an additional 146,664 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. Morgan Stanley increased their price target on United Therapeutics from $328.00 to $435.00 and gave the stock an "equal weight" rating in a research report on Friday, October 10th. Wells Fargo & Company initiated coverage on United Therapeutics in a research report on Monday. They issued an "underweight" rating and a $414.00 price objective on the stock. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a research report on Friday, September 5th. Jefferies Financial Group increased their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $461.62.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction on Monday, October 20th. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 4,000 shares of the firm's stock in a transaction on Monday, October 20th. The stock was sold at an average price of $424.59, for a total value of $1,698,360.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at $55,196.70. The trade was a 96.85% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 329,935 shares of company stock valued at $135,017,892. 10.30% of the stock is owned by company insiders.

United Therapeutics Stock Down 2.3%

UTHR stock opened at $422.53 on Wednesday. The business's fifty day moving average is $390.76 and its 200-day moving average is $329.82. The company has a market cap of $19.06 billion, a P/E ratio of 16.49, a price-to-earnings-growth ratio of 4.72 and a beta of 0.66. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $459.48.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period last year, the company earned $5.85 EPS. Research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.